αpd1-msln-car t cells
Cell therapyexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 26, 2020 (NCT04503980)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Programmed cell death protein 1Immunity, passive
PDCD1 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05944185 | Phase 1/Phase 2 (Phase 2) | Sep 30, 2023 | Chinese Academy of Medical Sciences, Shanghai Cell Therapy Group Co.,Ltd |
| NCT05373147 | Early Phase 1 (Phase 1) | Oct 30, 2020 | Shanghai Cell Therapy Group Co.,Ltd, Shanghai University |
| NCT04489862 | Early Phase 1 (Phase 1) | May 13, 2020 | Huazhong University of Science and Technology, Shanghai Cell Therapy Group Co.,Ltd |
| NCT04503980 | Early Phase 1 (Phase 1) | Mar 26, 2020 | Huazhong University of Science and Technology, Shanghai Cell Therapy Group Co.,Ltd |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shanghai Cell Therapy Group Co.,Ltd | For profit | 4 | 2 | 2 | 2020 |
| Huazhong University of Science and Technology | Academic/Hospital | 2 | 1 | 1 | 2020 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Shanghai University | Academic/Hospital | 1 | 1 | 1 | 2020 |
4 organizations
Page 1 / 1